Related Experiment Video
Updated: Jan 11, 2026
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
Identification of a Novel RUNX1::HMGN1 Fusion in Therapy Acute Myeloid Leukemia
1Yunnan Province Clinical Research Center for Hematologic Disease, Hu Yu Expert Workstation, Yunnan Province Major Difficult Diseases Traditional Chinese and Western Medicine Clinical Collaboration Pilot Project - Leukemia, Yunnan Provincial Clinical Medical Center for Blood Diseases and Thrombosis Prevention and Treatment, Yunnan Provincial Atherosclerosis Traditional Chinese and Western Medicine Collaborative Collaboration Base, The First People's Hospital of Yunnan Province, Kunming, China.
None:
Therapy acute myeloid leukemia (AML) is a heterogeneous malignant hematopoietic disease that arises either from an antecedent hematologic disorder, including myelodysplastic syndromes, myeloproliferative neoplasms, aplastic anemia, or as a result of exposure to genotoxic chemotherapeutic agents or radiotherapy (therapy-related AML). In this study, we describe a case of therapy AML after treatment for breast, uterine, and rectal malignancies in a patient with a special fusion gene-RUNX1::HMGN1.
